Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 17/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21093204 | 0.90 | RAB9A (0.60) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL2174228 | 0.90 | ALDH1A1 (0.59) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL30616279 | 0.90 | ALDH1A1 (0.59) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL5540923 | 0.90 | ALDH1A1 (0.53) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL30905509 | 0.89 | ALDH1A1 (0.59) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL30905503 | 0.89 | ALDH1A1 (0.59) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL1890105 | 0.86 | ALDH1A1 (0.59) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL21200929 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL22766451 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HSD17B10MAPK1CASP1CASP7 | |
| SCHEMBL6004614 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HSD17B10MAPK1CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023150535-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF | NERIO THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2022-02-01 | — | — | US | disclosed |
| US-20210355107-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210355107-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| EP-3845527-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | Beijing Yuezhikangtai Biomedicines Co., Ltd. (CN) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845527-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | Beijing Yuezhikangtai Biomedicines Co., Ltd. (CN) | 2021-07-07 | — | — | EP | disclosed |
| US-20210188778-A1 | NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-06-24 | — | — | US | disclosed |
| EP-3743417-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| EP-1724268-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6630489-B1 | Quinoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1157008-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050405-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-31 | — | — | WO | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355107-A1 | MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF | PDXK, ITK, JAK1 | ALDH1A1 973/4885HSD17B10 1507/4885MAPK1 166/4885 |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | ALDH1A1 2300/4885HSD17B10 2668/4885MAPK1 234/4885 |
| US-11236050-B2 | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof | UGT1A1, CYP4B1, CYP1B1 | ALDH1A1 275/4885HSD17B10 3440/4885MAPK1 671/4885 |
| US-20210188778-A1 | NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF | CYP4B1, UGT1A1, CYP3A4 | ALDH1A1 341/4885HSD17B10 3475/4885MAPK1 762/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | ALDH1A1 3263/4885HSD17B10 3264/4885MAPK1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.